{"id":1625,"date":"2024-10-01T23:38:57","date_gmt":"2024-10-02T03:38:57","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=1625"},"modified":"2026-10-11T18:47:39","modified_gmt":"2026-10-11T22:47:39","slug":"when-do-drug-patents-expire","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/when-do-drug-patents-expire\/","title":{"rendered":"When Do Drug Patents Expire? It Depends on Five Clocks"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"572\" src=\"https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2024\/10\/image-19.png\" alt=\"\" class=\"wp-image-39875\" srcset=\"https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2024\/10\/image-19.png 1024w, https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2024\/10\/image-19-300x168.png 300w, https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2024\/10\/image-19-768x429.png 768w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">AbbVie&#8217;s U.S. compound patent for Humira (adalimumab) expired in December 2016. [<a href=\"#ref-1\">1<\/a>] The first U.S. biosimilar, Amgen&#8217;s Amjevita, launched on January 31, 2023. [<a href=\"#ref-2\">2<\/a>] That is a gap of 73 to 74 months between the patent date and the market date (analysis, see methodology below). The patent had expired. Competition had not started.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This gap is the core problem in drug patent research. A patent expiration date is one date on one clock. Generic and biosimilar entry depends on several clocks, and each clock has its own owner, its own rules and its own source documents. This article explains each clock, shows how they interact in six real products, and gives a method to estimate when a specific drug will face competition.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Data in this article is current as of October 11, 2026. Statutory text and company filings are the main sources. DrugPatentWatch is mentioned where it helps a reader locate patent records. It is not used as proof for any factual claim.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The Short Answer: When Does a Drug Patent Expire?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A U.S. drug patent expires 20 years after the date its application was filed in the United States. [<a href=\"#ref-6\">6<\/a>] A patent term extension or adjustment can move that date later. [<a href=\"#ref-5\">5<\/a>] [<a href=\"#ref-6\">6<\/a>] Generic or biosimilar entry can happen earlier or later than the expiration date. FDA exclusivity, litigation and settlements can each change the entry date.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What Is the Statutory Term of a Drug Patent?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The statute says the term begins on the date the patent issues. It ends 20 years from the date the application was filed. [<a href=\"#ref-6\">6<\/a>] The clock starts at filing, not at FDA approval and not at launch.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Why Is the Expiration Date in a Database Not the Generic Entry Date?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A database date shows one patent. A drug can have many patents. It can also have FDA exclusivity that runs on a separate schedule. [<a href=\"#ref-4\">4<\/a>] A court can invalidate a patent early. A settlement can set an entry date that is later than the date a court might have allowed. The Eliquis section below shows this: the earliest possible launch date and the settlement date differ by 497 days. [<a href=\"#ref-12\">12<\/a>]<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What the Data Shows: Eight Findings About Drug Patent Expiration<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The findings below are written so that each one can be quoted alone. Figures marked &#8220;analysis&#8221; are calculations from the cited dates. They are not figures reported by the cited source.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>The Eight Findings That Matter<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Humira&#8217;s U.S. compound patent expired in December 2016. The first U.S. biosimilar launched on January 31, 2023. The gap is 73 to 74 months (analysis). [<a href=\"#ref-1\">1<\/a>] [<a href=\"#ref-2\">2<\/a>]<\/li>\n\n\n\n<li>I-MAK, a patent-reform advocacy group, counted 247 U.S. patent applications on Humira. It reports that 89% were filed after the drug&#8217;s 2002 approval. [<a href=\"#ref-3\">3<\/a>]<\/li>\n\n\n\n<li>Pfizer reports that the Eliquis composition patent expires in November 2026 and the formulation patent expires in 2031. Settled generic companies may launch on April 1, 2028. [<a href=\"#ref-12\">12<\/a>]<\/li>\n\n\n\n<li>The earliest Eliquis launch date in Pfizer&#8217;s filing is November 21, 2026. The settlement date is 497 days later (analysis). [<a href=\"#ref-12\">12<\/a>]<\/li>\n\n\n\n<li>The first generic Entresto launched in July 2025. The remaining patent in the Delaware case runs to November 9, 2026, about 16 months after July 2025 (analysis). [<a href=\"#ref-14\">14<\/a>] [<a href=\"#ref-16\">16<\/a>]<\/li>\n\n\n\n<li>Revlimid&#8217;s settlement set volume-limited generic entry after March 2022 and unlimited entry no earlier than January 31, 2026. That is a staircase of about 46 to 47 months (analysis). [<a href=\"#ref-17\">17<\/a>]<\/li>\n\n\n\n<li>Merck lists the Keytruda U.S. patent expiry as 2028. Two more patents in the compound family expire in 2029. [<a href=\"#ref-19\">19<\/a>]<\/li>\n\n\n\n<li>FDA data on products with first generic entry from 2015 to 2017 show a 39% lower generic price with one producer and price reductions of more than 95% with six or more. [<a href=\"#ref-21\">21<\/a>]<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How Was the Comparison Built? Methodology and Limits<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Data analyzed: dates for six products (Humira, Eliquis, Entresto, Revlimid, Lipitor and Keytruda). Time period: patent events from 2002 to 2031, with sources dated 2011 to 2026.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Selection: we included a product only when a primary document or a dated press release gave at least two relevant dates. Primary documents are SEC filings, company press releases, court orders and statutes. Where we used a trade-press report, the text says so. The sample is a selection, not a random draw. It cannot support claims about all drugs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Duplicates: each product has one record. We did not count two patents for the same product as two records.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Calculation: we measured gaps in calendar days. We converted days to months by dividing by 30.4375. When a source gave only a month, such as &#8220;December 2016&#8221;, we calculated from the first day and the last day of that month and report the range. When a source gave no launch day, we used the earliest date the court order allowed and say so.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Limits: patent status changes. Companies can amend filings. A date in an SEC filing is the company&#8217;s statement, not a court finding. Readers should check the current Orange Book, the court docket and the latest company filing before they rely on any date.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>How Long Does a U.S. Drug Patent Last After Filing?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The term is 20 years from the filing date. [<a href=\"#ref-6\">6<\/a>] A company usually files the first patent on the active ingredient early, before clinical trials. FDA approval comes years later. The years between filing and approval do not return to the company unless an extension applies.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Why Does a Drug Lose Patent Years Before Launch?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Clinical trials and FDA review take time. Grabowski and Vernon wrote that effective patent life is lost in pharmaceuticals because trials and regulatory approval take a long time. [<a href=\"#ref-11\">11<\/a>] A 1984 U.S. law restores part of the lost time. [<a href=\"#ref-11\">11<\/a>]<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>What Did the 1984 Hatch-Waxman Act Try to Do?<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The Congressional Research Service describes the Act as designed to encourage innovation in the pharmaceutical industry. [<a href=\"#ref-10\">10<\/a>] The Act also aimed to make generic drugs widely available while it kept incentives to develop new drugs. [<a href=\"#ref-10\">10<\/a>] The Act created the patent term restoration rule, the FDA exclusivity periods and the generic challenge process. The sections below cover each one.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>What Is Patent Term Adjustment Under 35 U.S.C. 154(b)?<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Patent term adjustment is separate from the extension for regulatory review. Section 154(b) sets three guarantees: prompt Patent Office responses, no more than 3 years of application pendency, and adjustments for delays from derivation proceedings, secrecy orders and appeals. [<a href=\"#ref-6\">6<\/a>] Patent term adjustment lengthens a patent because the Patent Office was slow. Patent term extension lengthens a patent because FDA review was slow. Do not confuse the two when you read a patent record.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>How Does Patent Term Extension Work Under 35 U.S.C. 156?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Patent term extension restores part of the time a product spent in testing and FDA review. The extension equals the regulatory review period for the approved product, with two reductions. [<a href=\"#ref-5\">5<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What Is the Extension Formula?<\/strong><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Testing Phase: Only Half Counts<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The statute includes only one-half of the time remaining in the testing phase. [<a href=\"#ref-5\">5<\/a>]<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Approval Phase: All of It Counts<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The approval-phase portion counts in full. [<a href=\"#ref-5\">5<\/a>] Fast clinical testing and slow FDA review give a longer extension per year of delay than the reverse.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What Are the Five-Year Cap and the 14-Year Ceiling?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The extension may not exceed five years for patents issued after the statute&#8217;s enactment, with exceptions in the statute. [<a href=\"#ref-5\">5<\/a>] A second limit applies: the total of the post-approval periods may not exceed 14 years. [<a href=\"#ref-5\">5<\/a>] The Congressional Research Service describes the same two limits. [<a href=\"#ref-10\">10<\/a>]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Illustration (not a real product): assume a patent would expire 10 years after approval, and the formula gives a 5-year extension. Ten plus five is 15 years, which is above the 14-year ceiling. The extension is cut to four years. This arithmetic shows why many extended patents end close to 14 years after approval.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What Is the 60-Day Application Deadline?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">An extension application may only be submitted within the 60-day period that begins on the date the product received permission for commercial marketing. [<a href=\"#ref-5\">5<\/a>] A company that misses the window loses the extension.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What Does This Mean for the &#8220;Effective Patent Life&#8221; Debate?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">DrugPatentWatch has published a separate explainer on how a 20-year term compresses into a shorter period of market protection. [<a href=\"#ref-23\">23<\/a>] The real figure differs by drug. It depends on filing date, trial length, review time and whether the company obtained an extension. Use the drug-level dates, not an industry average, when you model a specific product.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Regulatory Exclusivity: The Clock That Needs No Patent<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">FDA exclusivity is a right granted at approval. It does not depend on a patent. FDA lists patents and exclusivity as separate items in the Orange Book. [<a href=\"#ref-4\">4<\/a>] A drug with an expired patent can still be protected by exclusivity. A drug with exclusivity can also have patents that expire before or after it.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How Long Is New Chemical Entity Exclusivity?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">FDA lists new chemical entity exclusivity at 5 years. [<a href=\"#ref-4\">4<\/a>] The statute bars submission of a generic application until five years after approval of the original application. [<a href=\"#ref-10\">10<\/a>] The statute also sets a four-year point after which an application may be submitted. [<a href=\"#ref-7\">7<\/a>] Generic firms call that four-year point &#8220;NCE-1&#8221;. A generic company that files at NCE-1 starts a patent dispute with a long lead time.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How Long Are Orphan, New Clinical Investigation and Pediatric Exclusivity?<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th><strong>Exclusivity type<\/strong><\/th><th><strong>Length<\/strong><\/th><th><strong>What it blocks<\/strong><\/th><th><strong>Source<\/strong><\/th><\/tr><\/thead><tbody><tr><td>New chemical entity (NCE)<\/td><td>5 years<\/td><td>Generic applications<\/td><td>FDA FAQ [<a href=\"#ref-4\">4<\/a>]<\/td><\/tr><tr><td>New clinical investigation<\/td><td>3 years<\/td><td>Approval of generics that rely on the new studies<\/td><td>FDA FAQ [<a href=\"#ref-4\">4<\/a>]; statute [<a href=\"#ref-7\">7<\/a>]<\/td><\/tr><tr><td>Orphan drug (ODE)<\/td><td>7 years<\/td><td>Approval of the same drug for the same orphan use<\/td><td>FDA FAQ [<a href=\"#ref-4\">4<\/a>]<\/td><\/tr><tr><td>Pediatric (PED)<\/td><td>6 months added to existing patents and exclusivity<\/td><td>Generic approval after other protection ends<\/td><td>FDA FAQ [<a href=\"#ref-4\">4<\/a>]<\/td><\/tr><tr><td>Patent challenge (PC)<\/td><td>180 days, ANDAs only<\/td><td>Later generic filers<\/td><td>FDA FAQ [<a href=\"#ref-4\">4<\/a>]<\/td><\/tr><tr><td>Competitive generic therapy (CGT)<\/td><td>180 days, ANDAs only<\/td><td>Later generic filers<\/td><td>FDA FAQ [<a href=\"#ref-4\">4<\/a>]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA page is marked as current as of February 5, 2020. [<a href=\"#ref-4\">4<\/a>] Check the current Orange Book entry for any product you study.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>How Does Pediatric Exclusivity Change a Patent Date?<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">FDA states that a 6-month period of exclusivity is added to all existing patents and exclusivity. [<a href=\"#ref-4\">4<\/a>] The Entresto record shows the effect. U.S. Patent No. 8,101,659 had already expired, but pediatric exclusivity extended its life to July 15, 2025. [<a href=\"#ref-14\">14<\/a>] A six-month add-on applied to a drug that had about $7.8 billion in sales in 2024. [<a href=\"#ref-14\">14<\/a>]<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Biologics: When Does Biologic Exclusivity Expire?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Biologics follow a different statute. A biosimilar application cannot be submitted until 4 years after the reference product was first licensed. [<a href=\"#ref-8\">8<\/a>] FDA cannot make approval of a biosimilar effective until 12 years after first licensure. [<a href=\"#ref-8\">8<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What Are the 4-Year and 12-Year Periods?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The 4-year period is a filing bar. The 12-year period is an approval bar. [<a href=\"#ref-8\">8<\/a>] [<a href=\"#ref-9\">9<\/a>] Patents add a second layer. A biosimilar can clear the 12-year bar and still face patent litigation. The Humira record shows this in the case study below.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What Questions Are Still Open on Reference Product Exclusivity?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Alston and Bird reported in January 2026 that FDA has not finalized its guidance on reference product exclusivity. The main guidance document is an August 2014 draft. [<a href=\"#ref-9\">9<\/a>]<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Does Umbrella Exclusivity Apply to Biologics?<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The question is unsettled. [<a href=\"#ref-9\">9<\/a>]<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Does a Monoclonal Antibody Plus Hyaluronidase Get Its Own Exclusivity?<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">This question is also unsettled. It matters for products that switch from intravenous to subcutaneous delivery. [<a href=\"#ref-9\">9<\/a>] Reference product exclusivity determinations are not automatic. The Purple Book lists determinations, but a missing first-licensure date does not mean a product was ineligible. [<a href=\"#ref-9\">9<\/a>]<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What Happens at Paragraph IV? ANDA Litigation and the 30-Month Stay<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Most small-molecule entry dates come from this process. A generic company files an abbreviated new drug application and certifies that a listed patent is invalid or not infringed. This certification is called a Paragraph IV certification. [<a href=\"#ref-10\">10<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What Does the Orange Book List, and What Does It Prove?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The brand company submits patent information on Form FDA 3542. [<a href=\"#ref-4\">4<\/a>] FDA says its patent listing role is ministerial. [<a href=\"#ref-4\">4<\/a>] A listing is not an FDA opinion that the patent is valid. The listing starts the legal process. A court decides validity and infringement.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How Does the 30-Month Stay Work?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">If the patent owner sues within 45 days of notice, FDA must suspend approval of the generic until one of three events occurs. One event is the date 30 months after the patent owner received notice. [<a href=\"#ref-10\">10<\/a>] The CRS report is dated December 2000. Congress has amended parts of the process since then. Confirm the current rule in 21 U.S.C. 355 before you rely on a number. [<a href=\"#ref-7\">7<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What Is 180-Day Exclusivity?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">FDA lists a patent challenge exclusivity of 180 days for ANDAs only. [<a href=\"#ref-4\">4<\/a>] The CRS report describes it as a 180-day period awarded to the first applicant to file a Paragraph IV certification. [<a href=\"#ref-10\">10<\/a>] The period gives the first filer a head start against later generics.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Case Example: Lipitor and the Ranbaxy Entry Date<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Generic Lipitor (atorvastatin) could begin sales on November 30, 2011 under a 2008 agreement between Ranbaxy and Pfizer. [<a href=\"#ref-20\">20<\/a>] FDA approved the first generic that day. [<a href=\"#ref-20\">20<\/a>] Ranbaxy first asked FDA for approval in 2002, about nine years earlier (analysis). [<a href=\"#ref-20\">20<\/a>] Ranbaxy held 180-day exclusivity. [<a href=\"#ref-20\">20<\/a>] Watson launched an authorized generic under a five-year deal with Pfizer. [<a href=\"#ref-20\">20<\/a>]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Lipitor sales were about $7.8 billion in the 12 months to September 30, 2011, according to IMS Health data cited by the trade source. [<a href=\"#ref-20\">20<\/a>] Analysts quoted in the same report said Pfizer could retain as much as 40% of Lipitor sales in the coming months. [<a href=\"#ref-20\">20<\/a>] That figure is an analyst estimate, not a reported result.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Case Study: Humira Patent Timeline, 2016 to 2023<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Humira shows what happens when the compound patent expires but later patents remain. It is also a biologic, so the BPCIA process applied.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What Did the Compound Patent Expiry Change?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">AbbVie&#8217;s FY2016 Form 10-K says the U.S. composition of matter patent covering adalimumab expired in December 2016. [<a href=\"#ref-1\">1<\/a>] It says the equivalent European patent was expected to expire in most EU countries in October 2018. [<a href=\"#ref-1\">1<\/a>] It also says non-composition patents covering adalimumab in the United States expire no earlier than 2022. [<a href=\"#ref-1\">1<\/a>]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Humira had worldwide net revenues of about $16.1 billion in 2016, about 63% of AbbVie&#8217;s total net revenues. [<a href=\"#ref-1\">1<\/a>] The company was exposed to one product.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How Many Patent Applications Surrounded Humira?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">I-MAK counted 247 U.S. patent applications on Humira and said 89% were filed after the drug&#8217;s 2002 approval. [<a href=\"#ref-3\">3<\/a>] I-MAK is an advocacy group that argues for patent reform, so readers should treat its framing as a position. The count is a count of applications. It is not a count of granted patents. I-MAK&#8217;s report gives no Humira-specific count of granted patents.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>When Did the First Humira Biosimilar Launch?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Amgen and AbbVie settled their BPCIA litigation over Amjevita in 2017. [<a href=\"#ref-2\">2<\/a>] Amgen launched Amjevita (adalimumab-atto) in the U.S. on January 31, 2023. [<a href=\"#ref-2\">2<\/a>] One 40 mg Amjevita offering had a list price 55% below the Humira list price. A second offering was 5% below. [<a href=\"#ref-2\">2<\/a>]<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Analysis: The 73-to-74-Month Gap<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">From December 1, 2016 to January 31, 2023 is 2,252 days, or 74.0 months. From December 31, 2016 to January 31, 2023 is 2,222 days, or 73.0 months (analysis). The gap fits the 10-K statement that other U.S. patents ran to 2022 or later. [<a href=\"#ref-1\">1<\/a>] It also fits a settlement that set a 2023 entry date. [<a href=\"#ref-2\">2<\/a>]<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Case Study: Eliquis and the Four Dates in One Drug<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Eliquis (apixaban) from Bristol Myers Squibb and Pfizer has more than one date in the public record. Each date has a different source and a different meaning.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What Does Pfizer&#8217;s 10-K Say About Eliquis Patents?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Pfizer&#8217;s FY2025 Form 10-K gives the composition of matter patent expiry as November 2026 and the formulation patent expiry as 2031. [<a href=\"#ref-12\">12<\/a>] It says the settled generic companies may launch a generic Eliquis on April 1, 2028. [<a href=\"#ref-12\">12<\/a>] It says three generic companies may not launch until the 2031 expiry date. [<a href=\"#ref-12\">12<\/a>]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">It also says the settled generic companies and any successful future litigant could launch on November 21, 2026 if the formulation patent is held invalid or not infringed on appeal. [<a href=\"#ref-12\">12<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How Did the Federal Circuit Change the Eliquis Outlook?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">On September 3, 2021, the Federal Circuit upheld a Delaware ruling that the composition of matter patent and a formulation patent were valid. [<a href=\"#ref-13\">13<\/a>] Pfizer and Bristol Myers Squibb said the ruling protected Eliquis until April 1, 2028. Before the ruling, generic entry had been expected between 2026 and 2031. [<a href=\"#ref-13\">13<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Why Do the Dates Differ by Country?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Pfizer&#8217;s 10-K says the apixaban basic product patent and the associated supplementary protection certificate were invalidated in the United Kingdom. [<a href=\"#ref-12\">12<\/a>] The U.S. courts upheld the U.S. patents. [<a href=\"#ref-13\">13<\/a>] Patent expiry is national. A global launch plan needs one date per country.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Analysis: 497 Days Between the Two Dates<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">From November 21, 2026 to April 1, 2028 is 497 days, or 16.3 months (analysis). The earlier date depends on a future appeal result. [<a href=\"#ref-12\">12<\/a>] The later date is a contractual date for the settled companies. [<a href=\"#ref-12\">12<\/a>] A forecast should show both dates, and it should label the earlier one as contingent.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Case Study: Entresto and a Generic Launch Before the Last Patent Expired<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Entresto (sacubitril and valsartan) from Novartis was first approved in 2015. [<a href=\"#ref-14\">14<\/a>] It had more than $7.8 billion in sales in 2024. [<a href=\"#ref-14\">14<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Which Entresto Patents Were in Dispute?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Novartis asserted U.S. Patent No. 8,101,659 and U.S. Patent No. 11,096,918 against MSN in the District of Delaware in October 2022. [<a href=\"#ref-14\">14<\/a>] The &#8216;659 patent had expired but received pediatric exclusivity to July 15, 2025. [<a href=\"#ref-14\">14<\/a>] The &#8216;918 patent covers an amorphous solid form and is due to expire in November 2026. [<a href=\"#ref-14\">14<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What Did the Courts Decide?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In July 2024, Judge Richard Andrews denied Novartis&#8217;s request for a preliminary injunction. He found Novartis unlikely to succeed on the merits and found no showing of irreparable harm. [<a href=\"#ref-14\">14<\/a>] In April 2025, the Delaware court ordered FDA to reset MSN&#8217;s approval date to no earlier than July 16, 2025. [<a href=\"#ref-14\">14<\/a>] On June 13, 2025, the court issued an order confirming a settlement of part of the dispute. [<a href=\"#ref-14\">14<\/a>] In July 2025, a federal judge in Delaware ruled that Novartis could not block MSN&#8217;s launch. [<a href=\"#ref-15\">15<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>When Did Generic Entresto Launch?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">FDA approved the first generic versions in May 2024. The first generic launched commercially in July 2025. [<a href=\"#ref-16\">16<\/a>] The gap between approval and launch is about 14 months (analysis). The &#8216;659 patent date and the court orders are the documented events in that gap. [<a href=\"#ref-14\">14<\/a>]<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Analysis: Launch Before the Last Listed Patent Date<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The &#8216;918 patent expires in November 2026. [<a href=\"#ref-14\">14<\/a>] From July 15, 2025 to November 9, 2026 is 482 days, or 15.8 months (analysis). The sources do not give the exact launch day, so we used July 15, 2025, the pediatric exclusivity end date. [<a href=\"#ref-14\">14<\/a>] The launch happened about 16 months before the last patent in the Delaware case expired. A patent table sorted by latest expiry date would have predicted a later launch.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Case Study: Revlimid and the Settlement Staircase<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Revlimid (lenalidomide) shows a third pattern. Entry did not happen on one date. It rose in steps.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What Did the Dr. Reddy&#8217;s Settlement Set?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">On September 17, 2020, Bristol Myers Squibb announced a settlement with Dr. Reddy&#8217;s. [<a href=\"#ref-17\">17<\/a>] The release says Celgene licensed Dr. Reddy&#8217;s to sell volume-limited amounts of generic lenalidomide beginning some time after the March 2022 volume-limited license date granted to Natco. [<a href=\"#ref-17\">17<\/a>] It also says Dr. Reddy&#8217;s may sell an unlimited quantity beginning no earlier than January 31, 2026. [<a href=\"#ref-17\">17<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Were the Volume Limits Public?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. The release says the specific volume-limited license date and percentages for Dr. Reddy&#8217;s were not disclosed and are confidential. [<a href=\"#ref-17\">17<\/a>] The parties planned consent judgments in the U.S. District Court for the District of New Jersey. The judgments enjoin Dr. Reddy&#8217;s from marketing generic lenalidomide before the patents-in-suit expire, except as the settlement allows. [<a href=\"#ref-17\">17<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What Happened at Launch?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In September 2022, Dr. Reddy&#8217;s announced a U.S. launch of lenalidomide capsules. The release says two of six strengths were eligible for first-to-market 180-day exclusivity. [<a href=\"#ref-18\">18<\/a>]<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Analysis: A 46-to-47-Month Ramp<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">From March 1, 2022 to January 31, 2026 is 1,432 days, or 47.0 months. From March 31, 2022 to January 31, 2026 is 46.1 months (analysis). The staircase turns one patent date into a multi-year schedule. A model that uses one entry date overstates the first year of erosion and understates the last.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Keytruda: What Is Documented and What Is Projection?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Merck reports combined Keytruda and Keytruda Qlex worldwide sales of $31,680 million for 2025. [<a href=\"#ref-19\">19<\/a>] This section separates filed facts from projections. It labels each calculated figure as analysis.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What Does Merck&#8217;s 10-K Document?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Merck&#8217;s FY2025 10-K lists the Keytruda U.S. patent expiry as 2028. It says the compound patent family contains two additional patents that expire in 2029. [<a href=\"#ref-19\">19<\/a>] The sales line in the filing combines Keytruda and Keytruda Qlex. The filing also lists a September 2025 FDA approval across most adult solid tumor indications. [<a href=\"#ref-19\">19<\/a>] Merck also states that it expects Keytruda to be selected in 2027 for government price setting. [<a href=\"#ref-19\">19<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How Much Time Remains? (Calculated)<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">From October 11, 2026 to December 31, 2028 is 26.7 months. To December 31, 2029 is 38.7 months (analysis). These figures are upper bounds because the filing gives a year, not a day.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Documented: Patent Dates<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The 2028 and 2029 dates come from Merck&#8217;s filing. [<a href=\"#ref-19\">19<\/a>]<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Projected: Competitor Entry<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The filing does not give a biosimilar launch date. We do not give one. A biosimilar launch also depends on the reference product exclusivity rules, on patents outside the compound family and on the litigation process. [<a href=\"#ref-8\">8<\/a>] [<a href=\"#ref-9\">9<\/a>]<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The Five-Clock Model: An Original Framework for Drug Patent Expiration<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The model below is an original classification built for this article. It is not an industry standard. It sorts the dates that decide when competition begins.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Definitions: The Five Clocks<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th><strong>Clock<\/strong><\/th><th><strong>What starts it<\/strong><\/th><th><strong>Who sets the date<\/strong><\/th><th><strong>Example in this article<\/strong><\/th><\/tr><\/thead><tbody><tr><td>1. Patent clock<\/td><td>Patent filing, then issue<\/td><td>Statute and Patent Office [<a href=\"#ref-5\">5<\/a>] [<a href=\"#ref-6\">6<\/a>]<\/td><td>Humira compound patent, December 2016 [<a href=\"#ref-1\">1<\/a>]<\/td><\/tr><tr><td>2. Regulatory exclusivity clock<\/td><td>FDA approval or licensure<\/td><td>FDA and statute [<a href=\"#ref-4\">4<\/a>] [<a href=\"#ref-8\">8<\/a>]<\/td><td>Entresto pediatric exclusivity, July 15, 2025 [<a href=\"#ref-14\">14<\/a>]<\/td><\/tr><tr><td>3. Litigation clock<\/td><td>Paragraph IV notice or BPCIA suit<\/td><td>Courts [<a href=\"#ref-10\">10<\/a>]<\/td><td>Eliquis Federal Circuit ruling, September 3, 2021 [<a href=\"#ref-13\">13<\/a>]<\/td><\/tr><tr><td>4. Settlement clock<\/td><td>An agreement between parties<\/td><td>Brand and generic companies<\/td><td>Revlimid, January 31, 2026 [<a href=\"#ref-17\">17<\/a>]<\/td><\/tr><tr><td>5. Commercial-policy clock<\/td><td>Approval date and drug type<\/td><td>Medicare negotiation rules [<a href=\"#ref-22\">22<\/a>]<\/td><td>Keytruda selection expected 2027 [<a href=\"#ref-19\">19<\/a>]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The fifth clock does not block entry. It changes the value of the exclusivity that remains. The first four clocks decide whether a competitor can sell. The model is a checklist: for any drug, find the date on each clock, then ask which one binds.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Which Clock Bound in Each Case?<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th><strong>Product<\/strong><\/th><th><strong>Date or event<\/strong><\/th><th><strong>Later date or event<\/strong><\/th><th><strong>Gap (analysis)<\/strong><\/th><th><strong>Binding clock<\/strong><\/th><\/tr><\/thead><tbody><tr><td>Humira<\/td><td>U.S. compound patent expired, December 2016 [<a href=\"#ref-1\">1<\/a>]<\/td><td>Amjevita launch, January 31, 2023 [<a href=\"#ref-2\">2<\/a>]<\/td><td>73 to 74 months<\/td><td>Settlement and later patents<\/td><\/tr><tr><td>Eliquis<\/td><td>Earliest possible launch, November 21, 2026 [<a href=\"#ref-12\">12<\/a>]<\/td><td>Settlement launch, April 1, 2028 [<a href=\"#ref-12\">12<\/a>]<\/td><td>497 days<\/td><td>Settlement and litigation<\/td><\/tr><tr><td>Entresto<\/td><td>Pediatric exclusivity end, July 15, 2025 [<a href=\"#ref-14\">14<\/a>]<\/td><td>Last patent in the case expires, November 9, 2026 [<a href=\"#ref-14\">14<\/a>]<\/td><td>482 days (launch came first)<\/td><td>Regulatory exclusivity<\/td><\/tr><tr><td>Revlimid<\/td><td>Natco volume-limited date, March 2022 [<a href=\"#ref-17\">17<\/a>]<\/td><td>Unlimited entry, January 31, 2026 [<a href=\"#ref-17\">17<\/a>]<\/td><td>46 to 47 months<\/td><td>Settlement<\/td><\/tr><tr><td>Lipitor<\/td><td>First FDA request, 2002 [<a href=\"#ref-20\">20<\/a>]<\/td><td>Generic entry, November 30, 2011 [<a href=\"#ref-20\">20<\/a>]<\/td><td>About 9 years<\/td><td>Settlement date from 2008 agreement<\/td><\/tr><tr><td>Keytruda<\/td><td>U.S. patent expiry, 2028 [<a href=\"#ref-19\">19<\/a>]<\/td><td>Two further patents expire, 2029 [<a href=\"#ref-19\">19<\/a>]<\/td><td>About 1 year (projected)<\/td><td>Not yet determined<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The table shows that no single clock explains all six products. The settlement clock bound in four cases, with litigation also in play for Eliquis. The regulatory clock bound in one. Keytruda has no confirmed entry date.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What This Means for Generic Entry, Biosimilars and Brand Manufacturers<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What This Means for Generic Entry<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A generic company should build a date for each clock, not a single date. The Entresto record shows that a launch can occur before the last patent expires. [<a href=\"#ref-14\">14<\/a>] [<a href=\"#ref-16\">16<\/a>] The Lipitor record shows that a first filer can wait about nine years from filing to launch. [<a href=\"#ref-20\">20<\/a>] A first filer holds 180-day exclusivity. [<a href=\"#ref-4\">4<\/a>] That is a reason to file early and to track every Paragraph IV event.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What This Means for Biosimilars<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A biosimilar developer faces the 4-year and 12-year periods. [<a href=\"#ref-8\">8<\/a>] It must also plan for patents that do not expire on those dates. The Humira record shows a patent that expired in 2016 and a launch in 2023. [<a href=\"#ref-1\">1<\/a>] [<a href=\"#ref-2\">2<\/a>] Open questions about reference product exclusivity add uncertainty to subcutaneous reformulations. [<a href=\"#ref-9\">9<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What This Means for Brand Manufacturers<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A brand company controls the filing dates and the extension requests. The 60-day deadline for a patent term extension application leaves little room for error. [<a href=\"#ref-5\">5<\/a>] Settlements can protect revenue on a known schedule. The Eliquis and Revlimid records show settlements that set dates for entry. [<a href=\"#ref-12\">12<\/a>] [<a href=\"#ref-17\">17<\/a>] A brand company should model both a litigated outcome and a settled outcome.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What This Means for Investors and Analysts<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A forecast that uses the latest patent expiry as the loss-of-exclusivity date can be wrong in either direction. Entresto launched before its last listed patent expired. [<a href=\"#ref-14\">14<\/a>] [<a href=\"#ref-16\">16<\/a>] Humira launched years after its compound patent. [<a href=\"#ref-1\">1<\/a>] [<a href=\"#ref-2\">2<\/a>] Label each date as filed fact, contract term or projection.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What Happens to Drug Prices After a Patent Expires?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Prices fall as the number of generic producers rises. FDA measured this for products with first generic entry between January 2015 and December 2017. [<a href=\"#ref-21\">21<\/a>]<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">&#8220;generic prices using both AMP and invoice prices show price reductions of more than 95%&#8221; for products with six or more generic producers. (FDA, n.d.) [<a href=\"#ref-21\">21<\/a>]<\/p>\n<\/blockquote>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How Large Is the Price Drop by Number of Competitors?<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th><strong>Generic producers<\/strong><\/th><th><strong>Average manufacturer price reduction (FDA text)<\/strong><\/th><th><strong>Median reduction in FDA table (analysis from ratio)<\/strong><\/th><\/tr><\/thead><tbody><tr><td>1<\/td><td>39%<\/td><td>38.6%<\/td><\/tr><tr><td>2<\/td><td>54%<\/td><td>53.5%<\/td><\/tr><tr><td>4<\/td><td>79%<\/td><td>78.8%<\/td><\/tr><tr><td>6 or more<\/td><td>More than 95%<\/td><td>93.9% at exactly six producers<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">All figures come from the FDA report. [<a href=\"#ref-21\">21<\/a>] The median reduction is one minus the median generic-to-brand price ratio in the FDA table. That conversion is our calculation. The FDA text says six or more producers produce reductions above 95%. The table median for exactly six is about 94% for the manufacturer price measure and about 90% for the invoice measure. The text figure may reflect a pooled group that the table does not show. [<a href=\"#ref-21\">21<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How Was the Baseline Defined?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">FDA set each product&#8217;s brand price as the unit-sales-weighted average brand price in the three months before generic entry. [<a href=\"#ref-21\">21<\/a>] The generic price includes authorized generics, weighted by quantity sold. [<a href=\"#ref-21\">21<\/a>] Lipitor&#8217;s authorized generic is an example of that product type. [<a href=\"#ref-20\">20<\/a>]<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The Medicare Negotiation Clock: Is the Inflation Reduction Act a Second Cliff?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The Inflation Reduction Act added a price-setting rule that works on a schedule tied to approval date. Small-molecule drugs are exempt from negotiation for seven years after approval. Biologics get 11 years. [<a href=\"#ref-22\">22<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How Do the 9-Year and 13-Year Figures Arise?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Negotiated prices take effect two years after a drug is selected. That produces the widely cited nine-year timeline for small molecules and the 13-year timeline for biologics. [<a href=\"#ref-22\">22<\/a>] Eligibility is tied to the earliest approval across versions of the same active ingredient. [<a href=\"#ref-22\">22<\/a>] A new formulation does not restart the clock.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What Does This Mean for Keytruda?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Merck says it expects Keytruda to be selected in 2027 for government price setting. [<a href=\"#ref-19\">19<\/a>] The patent dates in the same filing are 2028 and 2029. [<a href=\"#ref-19\">19<\/a>] The selection date and the patent dates are close. A model for Keytruda needs both the commercial-policy clock and the patent clock.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>How to Find a Drug&#8217;s Patent Expiration Date: A Practical Method<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The steps below give a repeatable process. Use a patent database for step 1 and primary sources for steps 2 to 4.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Step 1: Collect the Listed Patents and Exclusivities<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Start with the Orange Book for small molecules and the Purple Book for biologics. [<a href=\"#ref-4\">4<\/a>] [<a href=\"#ref-9\">9<\/a>] DrugPatentWatch compiles Orange Book patent and exclusivity listings with litigation records, which helps with a first pass. Treat any compiled date as a lead to verify.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Step 2: Read the Company Filing<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">SEC filings state the company&#8217;s view of expiry dates and settlement terms. The Pfizer and Merck filings in this article are examples. [<a href=\"#ref-12\">12<\/a>] [<a href=\"#ref-19\">19<\/a>] Read the patent table and its footnotes. A footnote can hold the date that matters.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Step 3: Check the Court Record<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A court order can change a date. Read the order, not a summary, when the order decides validity or sets an approval date. The Entresto order resetting approval to no earlier than July 16, 2025 is an example. [<a href=\"#ref-14\">14<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Step 4: Label Each Date<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Label each date as filed fact, court finding, contract term, calculation or projection. Never present a projection as a confirmed event.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Key Takeaways<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>A U.S. drug patent ends 20 years after its filing date, before any extension or adjustment. [<a href=\"#ref-6\">6<\/a>]<\/li>\n\n\n\n<li>Patent term extension can add up to five years. Total post-approval protection cannot exceed 14 years. [<a href=\"#ref-5\">5<\/a>]<\/li>\n\n\n\n<li>FDA exclusivity runs apart from patents: 5 years for a new chemical entity, 7 for an orphan drug, 3 for a new clinical investigation, and 6 months of pediatric add-on. [<a href=\"#ref-4\">4<\/a>]<\/li>\n\n\n\n<li>A biosimilar application cannot be submitted until 4 years after first licensure, and approval cannot take effect until 12 years after. [<a href=\"#ref-8\">8<\/a>]<\/li>\n\n\n\n<li>Humira&#8217;s compound patent expired in December 2016. The first U.S. biosimilar launched on January 31, 2023, a gap of 73 to 74 months (analysis). [<a href=\"#ref-1\">1<\/a>] [<a href=\"#ref-2\">2<\/a>]<\/li>\n\n\n\n<li>Eliquis has a November 21, 2026 contingent launch date and an April 1, 2028 settlement date. The two differ by 497 days (analysis). [<a href=\"#ref-12\">12<\/a>]<\/li>\n\n\n\n<li>Entresto&#8217;s first generic launched in July 2025, about 16 months before the last patent in the Delaware case expires (analysis). [<a href=\"#ref-14\">14<\/a>] [<a href=\"#ref-16\">16<\/a>]<\/li>\n\n\n\n<li>FDA data show price reductions of more than 95% with six or more generic producers. [<a href=\"#ref-21\">21<\/a>]<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>FAQ<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Do drug patents expire 20 years after FDA approval?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. The term ends 20 years after the filing date, not the approval date. [<a href=\"#ref-6\">6<\/a>] Approval often comes many years after filing, so the market life of a patent is usually shorter than 20 years.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Can a drug patent be extended?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Yes. A patent term extension under 35 U.S.C. 156 can add time, up to five years, with a 14-year ceiling on total post-approval protection. [<a href=\"#ref-5\">5<\/a>] A separate patent term adjustment under section 154(b) compensates for Patent Office delay. [<a href=\"#ref-6\">6<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What is the difference between a patent and FDA exclusivity?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A patent is granted by the Patent Office. Exclusivity is granted by FDA at approval and does not require a patent. FDA lists them as separate items. [<a href=\"#ref-4\">4<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How long does biologic exclusivity last?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Twelve years from first licensure for approval of a biosimilar, with a four-year bar on submitting the application. [<a href=\"#ref-8\">8<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Does the Orange Book prove a patent is valid?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. FDA says its patent listing role is ministerial. [<a href=\"#ref-4\">4<\/a>] A court decides validity.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What is a Paragraph IV certification?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">It is a generic applicant&#8217;s statement that a listed patent is invalid or not infringed. A patent owner that sues within 45 days of notice can trigger a stay of FDA approval. [<a href=\"#ref-10\">10<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How much do prices fall when generics enter?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In FDA&#8217;s study of first entries from 2015 to 2017, the average manufacturer price fell 39% with one generic producer and 54% with two. [<a href=\"#ref-21\">21<\/a>] The FDA text reports reductions of more than 95% with six or more.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Can a patent be valid in one country and invalid in another?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Yes. Pfizer reports that the apixaban basic product patent and its supplementary protection certificate were invalidated in the United Kingdom. [<a href=\"#ref-12\">12<\/a>] U.S. courts upheld the U.S. patents. [<a href=\"#ref-13\">13<\/a>]<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>When will Keytruda face competition?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Merck&#8217;s filing lists a 2028 U.S. patent expiry and two more compound-family patents in 2029. [<a href=\"#ref-19\">19<\/a>] The filing gives no competitor launch date, so no date is confirmed.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How does Medicare price negotiation affect exclusivity?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Small-molecule drugs become eligible seven years after approval and biologics after 11. Negotiated prices take effect two years after selection. [<a href=\"#ref-22\">22<\/a>] The rule does not block generic entry. It changes revenue while a drug is still protected.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>References<\/strong><\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li>AbbVie Inc. (2017). <em>Form 10-K for the fiscal year ended December 31, 2016<\/em>. U.S. Securities and Exchange Commission. <a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/0001551152\/000155115217000004\/abbv-12312016x10k.htm\">https:\/\/www.sec.gov\/Archives\/edgar\/data\/0001551152\/000155115217000004\/abbv-12312016x10k.htm<\/a><\/li>\n\n\n\n<li>Goodwin Procter LLP. (2023, February). <em>Amgen launches Amjevita, first biosimilar to Humira in the United States<\/em>. <a href=\"https:\/\/www.goodwinlaw.com\/en\/insights\/blogs\/2023\/02\/amgen-launches-amjevitafirst-biosimilar-to-humira-in-the-united-states\">https:\/\/www.goodwinlaw.com\/en\/insights\/blogs\/2023\/02\/amgen-launches-amjevitafirst-biosimilar-to-humira-in-the-united-states<\/a><\/li>\n\n\n\n<li>I-MAK. (2021, September 22). <em>Overpatented, overpriced: How excessive pharmaceutical patenting is extending monopolies and driving up drug prices (Humira report, revised)<\/em>. <a href=\"https:\/\/www.i-mak.org\/wp-content\/uploads\/2021\/09\/i-mak.humira.report.3.final-REVISED-2021-09-22.pdf\">https:\/\/www.i-mak.org\/wp-content\/uploads\/2021\/09\/i-mak.humira.report.3.final-REVISED-2021-09-22.pdf<\/a><\/li>\n\n\n\n<li>U.S. Food and Drug Administration. (n.d.). <em>Frequently asked questions on patents and exclusivity<\/em> (content current as of February 5, 2020). <a href=\"https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/frequently-asked-questions-patents-and-exclusivity\">https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/frequently-asked-questions-patents-and-exclusivity<\/a><\/li>\n\n\n\n<li>Legal Information Institute, Cornell Law School. (n.d.). <em>35 U.S.C. 156: Extension of patent term<\/em>. <a href=\"https:\/\/www.law.cornell.edu\/uscode\/text\/35\/156\">https:\/\/www.law.cornell.edu\/uscode\/text\/35\/156<\/a><\/li>\n\n\n\n<li>Legal Information Institute, Cornell Law School. (n.d.). <em>35 U.S.C. 154: Contents and term of patent; provisional rights<\/em>. <a href=\"https:\/\/www.law.cornell.edu\/uscode\/text\/35\/154\">https:\/\/www.law.cornell.edu\/uscode\/text\/35\/154<\/a><\/li>\n\n\n\n<li>Legal Information Institute, Cornell Law School. (n.d.). <em>21 U.S.C. 355: New drugs<\/em>. <a href=\"https:\/\/www.law.cornell.edu\/uscode\/text\/21\/355\">https:\/\/www.law.cornell.edu\/uscode\/text\/21\/355<\/a><\/li>\n\n\n\n<li>Legal Information Institute, Cornell Law School. (n.d.). <em>42 U.S.C. 262: Regulation of biological products<\/em>. <a href=\"https:\/\/www.law.cornell.edu\/uscode\/text\/42\/262\">https:\/\/www.law.cornell.edu\/uscode\/text\/42\/262<\/a><\/li>\n\n\n\n<li>Alston &amp; Bird LLP. (2026, January 26). <em>Biological products regulation: Reference product exclusivity<\/em>. <a href=\"https:\/\/www.alston.com\/en\/insights\/publications\/2026\/01\/biological-products-regulation-rpe\">https:\/\/www.alston.com\/en\/insights\/publications\/2026\/01\/biological-products-regulation-rpe<\/a><\/li>\n\n\n\n<li>Schacht, W. H., &amp; Thomas, J. R. (2000, December 18). <em>Patent law and its application to the pharmaceutical industry: An examination of the Drug Price Competition and Patent Term Restoration Act of 1984 (&#8220;The Hatch-Waxman Act&#8221;)<\/em> (CRS Report RL30756). Congressional Research Service. <a href=\"https:\/\/www.everycrsreport.com\/files\/20001218_RL30756_396e07d924303b2c91b4dc5996888a701d6e49e5.html\">https:\/\/www.everycrsreport.com\/files\/20001218_RL30756_396e07d924303b2c91b4dc5996888a701d6e49e5.html<\/a><\/li>\n\n\n\n<li>Grabowski, H. G., &amp; Vernon, J. M. (2000). Effective patent life in pharmaceuticals. <em>International Journal of Technology Management, 19<\/em>(1\/2), 98-120. <a href=\"https:\/\/www.inderscience.com\/info\/e_inarticle.php?artid=2803\">https:\/\/www.inderscience.com\/info\/e_inarticle.php?artid=2803<\/a><\/li>\n\n\n\n<li>Pfizer Inc. (2026). <em>Form 10-K for the fiscal year ended December 31, 2025<\/em>. U.S. Securities and Exchange Commission. <a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/78003\/000007800326000026\/pfe-20251231.htm\">https:\/\/www.sec.gov\/Archives\/edgar\/data\/78003\/000007800326000026\/pfe-20251231.htm<\/a><\/li>\n\n\n\n<li>Fierce Pharma. (2021, September). <em>Bristol Myers, Pfizer score another win in their Eliquis patent defense, protecting the blockbuster until 2028<\/em>. <a href=\"https:\/\/www.fiercepharma.com\/pharma\/bristol-myers-pfizer-score-another-win-their-eliquis-defense-protecting-blockbuster\">https:\/\/www.fiercepharma.com\/pharma\/bristol-myers-pfizer-score-another-win-their-eliquis-defense-protecting-blockbuster<\/a><\/li>\n\n\n\n<li>ip fray. (2025, June 17). <em>Novartis and MSN settle part of chronic heart failure patent fight, but key patent remains<\/em>. <a href=\"https:\/\/ipfray.com\/novartis-and-msn-settle-part-of-chronic-heart-failure-patent-fight-but-key-patent-remains\/\">https:\/\/ipfray.com\/novartis-and-msn-settle-part-of-chronic-heart-failure-patent-fight-but-key-patent-remains\/<\/a><\/li>\n\n\n\n<li>GeneOnline. (2025, July 14). <em>Federal judge rules Novartis cannot block generic Entresto launch by MSN Pharmaceuticals until late 2026<\/em>. <a href=\"https:\/\/www.geneonline.com\/federal-judge-rules-novartis-cannot-block-generic-entresto-launch-by-msn-pharmaceuticals-until-late-2026\/\">https:\/\/www.geneonline.com\/federal-judge-rules-novartis-cannot-block-generic-entresto-launch-by-msn-pharmaceuticals-until-late-2026\/<\/a><\/li>\n\n\n\n<li>GoodRx. (n.d.). <em>Entresto generic: Frequently asked questions<\/em>. <a href=\"https:\/\/www.goodrx.com\/entresto\/entresto-generic-faqs\">https:\/\/www.goodrx.com\/entresto\/entresto-generic-faqs<\/a><\/li>\n\n\n\n<li>Bristol Myers Squibb. (2020, September 17). <em>Bristol Myers Squibb announces settlement of U.S. patent litigation for Revlimid (lenalidomide) with Dr. Reddy&#8217;s<\/em>. Business Wire; BioSpace. <a href=\"https:\/\/www.biospace.com\/bristol-myers-squibb-announces-settlement-of-u-s-patent-litigation-for-revlimid-lenalidomide-with-dr-reddy-s\">https:\/\/www.biospace.com\/bristol-myers-squibb-announces-settlement-of-u-s-patent-litigation-for-revlimid-lenalidomide-with-dr-reddy-s<\/a><\/li>\n\n\n\n<li>Dr. Reddy&#8217;s Laboratories. (2022, September 7). <em>Dr. Reddy&#8217;s Laboratories announces the launch of lenalidomide capsules in the U.S. with two of six strengths eligible for first-to-market 180-day exclusivity<\/em>. Business Wire. <a href=\"https:\/\/www.businesswire.com\/news\/home\/20220907006110\/en\/Dr.-Reddys-Laboratories-Announces-the-Launch-of-Lenalidomide-Capsules-in-the-U.S.-With-Two-of-Six-Strengths-Eligible-for-First-to-market-180-day-Exclusivity\">https:\/\/www.businesswire.com\/news\/home\/20220907006110\/en\/<\/a><\/li>\n\n\n\n<li>Merck &amp; Co., Inc. (2026). <em>Form 10-K for the fiscal year ended December 31, 2025<\/em>. U.S. Securities and Exchange Commission. <a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/310158\/000031015826000063\/mrk-20251231.htm\">https:\/\/www.sec.gov\/Archives\/edgar\/data\/310158\/000031015826000063\/mrk-20251231.htm<\/a><\/li>\n\n\n\n<li>Manufacturing Chemist. (2011, November 30). <em>Pfizer patent on Lipitor expires<\/em>. <a href=\"https:\/\/manufacturingchemist.com\/pfizer-patent-on-lipitor-expires-65889\">https:\/\/manufacturingchemist.com\/pfizer-patent-on-lipitor-expires-65889<\/a><\/li>\n\n\n\n<li>U.S. Food and Drug Administration. (n.d.). <em>Generic competition and drug prices: New evidence linking greater generic competition and lower generic drug prices<\/em>. <a href=\"https:\/\/fda.gov\/media\/133509\/download\">https:\/\/fda.gov\/media\/133509\/download<\/a><\/li>\n\n\n\n<li>Healthcare Dive. (2023). <em>CMS Medicare drug price negotiations: Initial guidance<\/em>. <a href=\"https:\/\/www.healthcaredive.com\/news\/cms-medicare-drug-price-negotiations-initial-guidance\/645230\/\">https:\/\/www.healthcaredive.com\/news\/cms-medicare-drug-price-negotiations-initial-guidance\/645230\/<\/a><\/li>\n\n\n\n<li>DrugPatentWatch. (n.d.). <em>The math of monopoly: Why a 20-year drug patent lasts only 12 years<\/em>. <a href=\"https:\/\/www.drugpatentwatch.com\/blog\/the-math-of-monopoly-why-a-20-year-drug-patent-lasts-only-12-years\/\">https:\/\/www.drugpatentwatch.com\/blog\/the-math-of-monopoly-why-a-20-year-drug-patent-lasts-only-12-years\/<\/a><\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie&#8217;s U.S. compound patent for Humira (adalimumab) expired in December 2016. [1] The first U.S. biosimilar, Amgen&#8217;s Amjevita, launched on [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":39875,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-1625","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/1625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=1625"}],"version-history":[{"count":0,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/1625\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/39875"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=1625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=1625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=1625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}